Significant inhibition of the invasive capacity of human breast cancer cells [38] and ovarian cancer cells [39] in vitro, coupled with a decrease in MMP9 expression has also been observed with everolimus treatment. This evidence concerns the gene MMP9 and ovarian carcinoma.